SCHEMBL2368892

SCHEMBL2368892

Cc1sc2nc(N(CCO)CCO)nc(NCc3ccccn3)c2c1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 8/20 0.48
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
PRKCI P41743 1/20 0.43
TNF P01375 1/20 0.42
MAPK1 P28482 1/20 0.42
NOD1 Q9Y239 1/20 0.42
KCNA5 P22460 9/20 0.42
CDK2 P24941 3/20 0.42
CCNE1 P24864 2/20 0.42
JAK2 O60674 2/20 0.42
TYK2 P29597 2/20 0.42
GSK3B P49841 2/20 0.42
JAK3 P52333 2/20 0.42
BTK Q06187 2/20 0.42
AURKB Q96GD4 2/20 0.42
IRAK4 Q9NWZ3 2/20 0.42
IGF1R P08069 1/20 0.42
PIM1 P11309 1/20 0.42
SRC P12931 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368637 0.93 KCNA5 (0.43) KCNH2MEN1KMT2APRKCITNF
SCHEMBL2368489 0.89 PRKCI (0.41) KCNH2PRKCICDK2CCNE1CSNK2A2
SCHEMBL2368717 0.87 MEN1 (0.45) KCNH2MEN1KMT2ATNFMAPK1
SCHEMBL2369514 0.86 CLK4 (0.46) KCNH2MEN1KMT2AMAPK1KCNA5
SCHEMBL2368922 0.83 KCNH2 (0.48) KCNH2MEN1KMT2APRKCITNF
SCHEMBL2368953 0.83 KCNH2 (0.48) KCNH2MEN1KMT2APRKCITNF
SCHEMBL2368814 0.82 TNF (0.62) KCNH2TNFMAPK1NOD1KCNA5
SCHEMBL3385287 0.81 PRKCI (0.51) KCNH2MEN1KMT2APRKCITNF
SCHEMBL3382594 0.81 KCNH2 (0.49) KCNH2MEN1KMT2APRKCITNF
SCHEMBL2368976 0.81 KCNH2 (0.48) KCNH2MEN1KMT2APRKCITNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 KCNH2 6/4885MEN1 265/4885KMT2A 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.